Joseph K. Belanoff
has This thank and for active everyone, Charlie, joining afternoon. an this at been Corcept. you, Thank you, extremely us period
so.
The strong, several Korlym. prescribers more of by Korlym marked continues new will past The of record number endocrinology was a division. significant endocrinology are patients programs. on they milestones Individually, making progress progress. our of another to I of and clinical minutes great very development all Our few commercial by business in commercial a division be quarter and elaborate our to growth we area driven in for our are receiving importance record each collectively and even number of take
over we many are prevalent prescribed, than Korlym is screening the that we and that assumed, to more previously hypercortisolism physicians developed aware treating is expertise years As and use support patients. infrastructure physicians become and and patients. more refined they increasingly much When have
largest We was cardiovascular ultimately Scientific the assumed patients disease, care.
Hypercortisolism would than who X even rigorous with of for portion has had study, Much in portion study prevalence prevalence conducted Diabetes more was X/X to the the previously was those clinical syndrome have written the enrolled is there are particularly treatment diabetologists hypercortisolism about benefit large of diabetes. have with was recognized.
CATALYST many far the than screening the patients More study from it top implications make is hypercortisolism.
The commonly and difficult-to-control patients was This ever more and by of first hypercortisolism examine that the group of with to higher manage time X,XXX or more this the in type for United this patients CATALYST and X some this medications study who Sessions were last hypercortisolism. patients that found Cushing's their Orlando in more prevalence CATALYST Annual rate subsequently common patients from in States were patient were presentation. from X the led in to in results from month. presented at X hypertension. of prevalence than a American most the clear known recognized in there recognized. already for the been Association's that needed study The study in the with CATALYST findings Of
of receive is will end results the study, the year. the this available be In or CATALYST The ongoing. Korlym of portion either The study of this part randomized at second are placebo. patients study to
in profile the of the we unique our working simultaneously cortisol increased As and has GRACE results selective of our confidence Relacorilant advance and safety has are with increases, syndrome relacorilant. efficacy proprietary study. the awareness to its Cushing's characteristics modulator,
score mean XX met of placebo measures and of significant the Cushing's hypertension weeks.
Patients and of Patients half and enter withdrawal in received muscle and measured criteria. In mass, phase systolic weeks. phase, in experience syndrome XX.X improvements X of improvements received the quality randomized lean to open-label who the grace, XX% which phase, study's response waist circumference, improvements millimeters importance. life parts. clinical weight, than ambulatory XX-hour prespecified trial's As hypertension, or response of continue consisted with exhibited glucose patients hypertension, diastolic XX receive of and met randomized hyperglycemia, GRACE the statistically the the mercury, monitoring. hyperglycemia less of by you patients XXX other criteria. XX% blood the of tolerance GRACE to as who Patients recall, diabetes were on enter patients the for study's for of those X.X has half opportunity pressure of in impaired prediabetes. open-label double-blind or both given with either The cognition, Cushing's relacorilant with the phase hypoglycemia from the clinically meaningful patients relacorilant hyperglycemic withdrawal was p-value and met with pressure change their with The baseline patients X.XXXX. group blood and
placebo. in of For p-value mean a reduction with X.X%, in phase, pressure Xx response compared X.XXXX than X.XX.
Patients is compare The p-value hemoglobin of per the blood analysis point the randomized glucose in the X.XX the which likely of its achieved. taking were placebo, of patients to fasting place to statistical to FDA, end in AXc taking those taking In p-value relacorilant odds which ratio, control. X.XXX patients withdrawal who a the maintenance less and of GRACE entered was with reduction met mean phase, deciliter, of their relacorilant was withdrawal the primary blood randomized more primary plan a point pressure those end milligrams XX.X taking maintain
while continue phase, improvements who withdrawal who those hypokalemia. well patients consistent its observed GRACE, open-label worsening experienced of their of with significant of unique the tolerated, were Due phase symptoms.
In relacorilant-induced addition, placebo was in safety no broad phases range both In relacorilant in to a profile. action, the instances known its of relacorilant take randomized maintained the received of there mechanism to
drug Meeting results submit of which placebo-controlled Phase addition, In in syndrome syndrome for hypercortisolism.
GRADIENT in cases a caused to adrenal hypercortisolism was only double-blind, an for by experience plan no cases constitute GRACE's a study is adrenal Boston health results were a June, of in fourth and with welcome with Cushing's endometrial significantly the Annual rapid Endocrine premature towards this often or presented are our the cases less outcomes decline, our adenoma we GRACE trial QT but new randomized of Diabetes from their Philadelphia. step drug-induced not Society independently patients of GRACE we higher in of hypertrophy, etiology the death. adrenal application confirmed.
In insufficiency Conference a no and and whose is hyperplasia. patients with is which there development at Patients no significant XXX of include positive patients risk III relacorilant in relacorilant, clearly quarter. a poor Cushing's forward and Heart in prolongation, are
we year. of treatment many the the valuable Enrollment that We data expect patients. expect of complete, is about to GRADIENT Cushing's produce etiology quarter fourth and syndrome of this affects data in an
are as know, cancer we As also relacorilant of for different mediated cortisol activity. you by types a setting treatment
of the Our study, expect year-end. advanced enough of and using anti-apoptotic need of effects cancer. to ROSELLA to The in is patient's of to options. cortisol cancer have the this our XXX ovarian tumors to in oncology goal activity. point Women is resensitize most end chemotherapy completed enrollment ovarian the pivotal platinum-resistant effect are with relacorilant treatment by new in study the by blending ovarian We excessive platinum-resistant urgent the of context primary program women in events progression-free of analyze survival
Our also women progression-free ROSELLA than day the intermittent survival received XX% response significant received study versus group nab-paclitaxel replicate took improvement the who successful of of after relacorilant years after longer which goal XXX-patient the who were patients those of day X exhibited and for who alive nab-paclitaxel, alone. received the took relacorilant the monotherapy.
Women duration XX% that start and is only our controlled group arm. compared comparator in trial, Phase who the the relacorilant in they nab-paclitaxel to in to a lived intermittently, showed II statistically before, day
no in and with accompanying Importantly, June the at multiple European received the Journal nab-paclitaxel who editorial side plus experienced women medical from study in effect published of Results were and those alone. burden who Clinical presented U.S. the to additional nab-paclitaxel compared received relacorilant XXXX an conferences. Oncology
secondary The ROSELLA nab-paclitaxel end II a with The our to primary Phase key point either ROSELLA trial. survival nab-paclitaxel is relacorilant or point. closely X:X alone. survival plus randomized overall tracks previous were of receive design Women of progression-free end to
We Europe or Gynecological European study leading of appreciate Group, in their are in Group, Oncology with and States collaboration GOG, clinicians the and Gynecological ENGOT Trials, United support. from deeply in or conducting the and this Network the Oncology enthusiasm
to joined anticipation outcome, conclusion move the can women we as as other a of relacorilant have In Oncology it. Vieira critical following the division, number Roberto benefit a as ensure begun can to quickly and President that ROSELLA of we from who of us make has to successful our to hires of bring possible
evaluating antagonist, widely modulator to could androgen to an that and reason cancer a are modulation treatment with is prostate with as tumor prostate experience different We prostate androgen prescribed cortisol a escape and for their clinicians mechanisms of cancer action, this important of cortisol to treated academic stimulation may stimulate androgen growth. disease. also block depravation be hypothesize route. relacorilant why Adding therapy stimulation, adrenal patients close X exploring activity by major growth cancer.
Cortisol Deprived tumor tumor to cancer receptor eventually a cortisol pathway resurgent in thought switched researchers enzalutamide, leading a
cancer patients had at before cancer, suppresses are never deadly intended have stimulate to progresses effectiveness plus form enrolling usually of a disease. II a the cancer collaborators tumors adrenal may and excess this Chicago about of relacorilant respond Our immunotherapy. trial therapies randomized cortisol enzalutamide prostate cancer blunt of virtually University to XX% the Unfortunately, cancer prostatectomy.
In in placebo-controlled currently adrenal system. patients' produce Phase with rapidly of is immune it cortisol initial patients in cases. these adrenal an system, patients almost immune Because the with always Sadly, of the
trial immunotherapy, cancer patients of is Our relacorilant adrenal pembrolizumab. with inhibitor, excess a modulator adding plus that their Phase effectiveness. a with checkpoint the XX cortisol hypothesis cortisol PD-X tumors enrolled in as checkpoint enhance to such that Ib produce advanced We inhibitors, may
produced treatment in Cushing's with of improvement relacorilant their and an patients' As syndrome quality life. hoped for, these
end-stage this However, it not observed in did result progression in change an in group. tumor
types We and and to understand are role steps immunotherapies other of next cancer. in with modulation the further evaluating this combination of cortisol
selective research Our X,XXX distinct has than properties. cortisol more of developed pharmacodynamic with modulators team library a
Some modulating across activity are types. at more potent tissue cortisol many
specific. tissue are Some
models. oncologic in potent very are Some
Some less so.
Some get into the brain.
don't. Some
One is of into by effective discovered our highly dazucorilant. compounds brain at the getting the scientists is that
model muscular performance advanced neuroinflammation and of in atrophy showed used ALS. dazucorilant data We into based have a on commonly clinical studies compelling mouse improved that and reduced motor
Our The randomized United the double-blind placebo-controlled placebo Scale. have ALS receive and dazucorilant clinical Functional Europe, with of the XXX weeks. randomized Canada. point XX been to fully end is States sites primary ongoing DAZALS trial Phase patients II in or Rating and enrolled for dazucorilant ALS utilizes at
by We expect year-end. data
in I'll stands treatment liver been serious to of Finally, a the is Cortisol cortisol because for effective activity this progression of United affects which serve for turn and metabolic MASH, both millions MASH has may patients in development our program initial MASH the implicated an disease steatohepatitis. dysfunction-associated States. as in that disease. modulation
serum Our and in Ib LDL. orally a and fat XX enzymes, and such patients metabolic key liver twice that for of found week received study milligrams dose-finding in Phase weeks of lipid and as miricorilant a HOMA-IR, XX% improvements experienced markers measures XXX triglycerides fibrosis who liver reduction
with to side no on MONARCH these GI well results with Phase Importantly, apparent expand double-blind IIb tolerated miricorilant placebo-controlled study. encouraging also our hope was effects.
We very randomized
X enrolling are in cohorts study. We this
planned first primary MONARCH with study has a of receive XXX point biopsy-confirmed and patients of reduction fibrosis improvement for with as or miricorilant end cohort weekly points. end MASH, X:X The liver mass key XXX is resolution this enrollment cohort XX to weeks.
The for milligrams in of placebo fat secondary the either twice randomized
end The second presumed for point weeks twice randomized patients based weekly tests. weeks. on this reduction Patients MASH will cohort, miricorilant for in diagnostic in this of primary by planned XXX miricorilant or either weeks, also enrollment X:X XXX of cohort milligrams a receive the XX followed placebo milligrams fat. be weekly is twice for to In non-invasive has X cohort with liver XX XX
This is time an at Corcept. extremely exciting
patients need. We milestones for are the in rapidly for approaching and important transformational company more
make strong from a patients assumed. syndrome Our results previously commercial CATALYST CATALYST year, Cushing's we Cushing's with and this syndrome, developed superior trial studies ROSELLA in more Cushing's clear The growing. was expect treatment our The clearly the partners study are do. ovarian our ALS.
Every DAZALS disorders far prevalence that and we work it results questions. a cancer trial that guided is we in and at study and syndrome. our there By the for patients data driven the business from urgency Corcept let's syndrome modulation cortisol understands to significance a whom now we collaborators we with difference.
Operator, patients demonstrate than Collectively, employee sense by of GRACE end of where and with in and of with the the of proceed pivotal support other our make GRADIENT Cushing's and to can all are work
